Compare Divis Laboratories with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ORCHID PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ORCHID PHARMA DIVIS LABORATORIES/
ORCHID PHARMA
 
P/E (TTM) x 58.0 -130.1 - View Chart
P/BV x 15.5 37.3 41.6% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 DIVIS LABORATORIES   ORCHID PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ORCHID PHARMA
Sep-13
DIVIS LABORATORIES/
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639194 845.0%   
Low Rs1,11535 3,185.7%   
Sales per share (Unadj.) Rs186.3276.5 67.4%  
Earnings per share (Unadj.) Rs51.0-79.2 -64.3%  
Cash flow per share (Unadj.) Rs57.3-43.5 -131.9%  
Dividends per share (Unadj.) Rs16.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs261.853.9 485.3%  
Shares outstanding (eoy) m265.4770.45 376.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.40.4 1,784.7%   
Avg P/E ratio x27.0-1.4 -1,869.6%  
P/CF ratio (eoy) x24.0-2.6 -911.8%  
Price / Book Value ratio x5.32.1 247.8%  
Dividend payout %31.40-   
Avg Mkt Cap Rs m365,5928,067 4,532.2%   
No. of employees `00011.82.8 423.1%   
Total wages/salary Rs m5,4232,527 214.6%   
Avg. sales/employee Rs Th4,175.16,956.1 60.0%   
Avg. wages/employee Rs Th457.7902.5 50.7%   
Avg. net profit/employee Rs Th1,141.8-1,993.0 -57.3%   
INCOME DATA
Net Sales Rs m49,46319,477 254.0%  
Other income Rs m1,556407 382.2%   
Total revenues Rs m51,01919,884 256.6%   
Gross profit Rs m18,7181,103 1,697.7%  
Depreciation Rs m1,6892,519 67.0%   
Interest Rs m355,227 0.7%   
Profit before tax Rs m18,551-6,236 -297.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m5,023-125 -4,012.2%   
Profit after tax Rs m13,527-5,580 -242.4%  
Gross profit margin %37.85.7 668.5%  
Effective tax rate %27.12.0 1,348.8%   
Net profit margin %27.3-28.7 -95.5%  
BALANCE SHEET DATA
Current assets Rs m46,50111,014 422.2%   
Current liabilities Rs m8,46832,060 26.4%   
Net working cap to sales %76.9-108.1 -71.2%  
Current ratio x5.50.3 1,598.5%  
Inventory Days Days13195 137.9%  
Debtors Days Days8634 255.8%  
Net fixed assets Rs m25,79729,440 87.6%   
Share capital Rs m531705 75.4%   
"Free" reserves Rs m68,9622,043 3,376.2%   
Net worth Rs m69,4933,800 1,828.8%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m80,38346,510 172.8%  
Interest coverage x531.0-0.2 -274,968.8%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.60.4 146.9%   
Return on assets %16.9-0.8 -2,219.9%  
Return on equity %19.5-146.9 -13.3%  
Return on capital %26.7-3.7 -716.1%  
Exports to sales %037.9 0.0%   
Imports to sales %24.622.6 108.9%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs m12,1874,406 276.6%   
Fx inflow Rs m41,2387,513 548.9%   
Fx outflow Rs m12,4055,649 219.6%   
Net fx Rs m28,8331,865 1,546.4%   
CASH FLOW
From Operations Rs m9,5431,682 567.5%  
From Investments Rs m-6,854-9,860 69.5%  
From Financial Activity Rs m-2,4596,644 -37.0%  
Net Cashflow Rs m230-1,535 -15.0%  

Share Holding

Indian Promoters % 52.0 32.3 161.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 4.6 256.5%  
FIIs % 19.0 3.3 575.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.2 55.3 31.1%  
Shareholders   31,796 84,811 37.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


May 6, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS